TAXATION
Mutual Fund Distributions: How Capital Gain Distributions Are Taxed
For mutual fund investors, taxes are inevitable. Even if you’re a long-term buy...
Fidelity® Select Pharmaceuticals Port
- FPHAX
- Price as of: Oct 22, 2020
-
$23.72
N/A N/A
- Primary Theme
- Health Care Sector Equity
- Fund Company
- Fidelity Investments
- Share Class
FPHAX - Snapshot
Vitals
- YTD Return 2.4%
- 3 Yr Annualized Return 13.5%
- 5 Yr Annualized Return 8.0%
- Net Assets $856 M
- Holdings in Top 10 67.5%
52 WEEK LOW AND HIGH
$23.72
$18.08
$25.07
Expenses
OPERATING RELATED FEES
- Expense Ratio 0.78%
SALES FEES
- Front Load N/A
- Deferred Load N/A
BROKERAGE FEES
- Turnover 52.00%
TRADING FEES
- Max Redemption Fee N/A
Min Investment
- Standard (Taxable) $0
- IRA $2,500
Fund Classification
-
Primary Theme
Health Care Sector Equity
- Fund Type Open End Mutual Fund
- Investment Style Health
FPHAX - Profile
Distributions
- YTD Total Return 2.4%
- 3 Yr Annualized Total Return 13.5%
- 5 Yr Annualized Total Return 8.0%
- Capital Gain Distribution Frequency Semi-Annually
- Net Income Ratio 1.36%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Semi-Annually
Fund Details
-
Legal NameFidelity® Select Pharmaceuticals Portfolio
-
Fund Family NameFidelity Investments
-
Inception DateJun 18, 2001
-
Shares OutstandingN/A
-
Share ClassNo Load
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerKarim Suwwan de Felipe
Fund Description
The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
FPHAX - Performance
Return Ranking - Trailing
| Period | FPHAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 2.4% | -8.6% | 106.7% | 90.74% |
| 1 Yr | 26.1% | 8.3% | 128.7% | 58.39% |
| 3 Yr | 13.5%* | 0.1% | 38.7% | 22.38% |
| 5 Yr | 8.0%* | 0.4% | 30.0% | 76.98% |
| 10 Yr | 13.8%* | 8.9% | 20.1% | 71.54% |
* Annualized
Return Ranking - Calendar
| Period | FPHAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 21.0% | 3.8% | 63.8% | 48.97% |
| 2018 | 3.8% | -49.7% | 21.5% | 8.03% |
| 2017 | 8.9% | -59.8% | 54.4% | 82.96% |
| 2016 | -17.2% | -36.6% | 11.6% | 61.24% |
| 2015 | -3.8% | -62.4% | 27.9% | 69.67% |
Total Return Ranking - Trailing
| Period | FPHAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 2.4% | -8.6% | 102.1% | 90.74% |
| 1 Yr | 26.1% | 2.7% | 128.7% | 55.90% |
| 3 Yr | 13.5%* | 0.1% | 38.7% | 20.28% |
| 5 Yr | 8.0%* | 0.4% | 30.0% | 74.10% |
| 10 Yr | 13.8%* | 8.9% | 20.1% | 70.73% |
* Annualized
Total Return Ranking - Calendar
| Period | FPHAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 21.0% | 3.8% | 63.8% | 48.97% |
| 2018 | 4.4% | -25.3% | 22.2% | 7.30% |
| 2017 | 10.7% | -10.8% | 54.4% | 88.15% |
| 2016 | -16.3% | -36.6% | 11.6% | 68.99% |
| 2015 | 8.3% | -16.6% | 27.9% | 28.69% |
NAV & Total Return History
FPHAX - Holdings
Concentration Analysis
| FPHAX | Category Low | Category High | FPHAX % Rank | |
|---|---|---|---|---|
| Net Assets | 856 M | 2.6 M | 48.7 B | 50.87% |
| Number of Holdings | 63 | 26 | 431 | 73.99% |
| Net Assets in Top 10 | 607 M | 670 K | 18.8 B | 36.42% |
| Weighting of Top 10 | 67.54% | 13.2% | 76.3% | 3.47% |
Top 10 Holdings
- AstraZeneca PLC ADR 10.67%
- Bristol-Myers Squibb Company 9.33%
- Sanofi SA ADR 9.30%
- Roche Holding AG Dividend Right Cert. 7.71%
- Johnson & Johnson 7.12%
- Eli Lilly and Co 5.91%
- Merck & Co Inc 4.91%
- Zoetis Inc Class A 4.37%
- Novartis AG ADR 4.23%
- Amgen Inc 3.99%
Asset Allocation
| Weighting | Return Low | Return High | FPHAX % Rank | |
|---|---|---|---|---|
| Stocks | 99.21% | 61.47% | 100.59% | 42.20% |
| Cash | 0.70% | -0.68% | 32.46% | 60.69% |
| Other | 0.10% | -3.06% | 6.07% | 28.90% |
| Preferred Stocks | 0.00% | 0.00% | 6.63% | 33.53% |
| Convertible Bonds | 0.00% | 0.00% | 0.03% | 22.54% |
| Bonds | 0.00% | 0.00% | 16.11% | 24.86% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | FPHAX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 61.81% | 100.00% | 9.83% |
| Utilities | 0.00% | 0.00% | 0.00% | 21.39% |
| Technology | 0.00% | 0.00% | 20.28% | 32.95% |
| Real Estate | 0.00% | 0.00% | 6.03% | 27.17% |
| Industrials | 0.00% | 0.00% | 6.39% | 27.17% |
| Financial Services | 0.00% | 0.00% | 2.72% | 50.87% |
| Energy | 0.00% | 0.00% | 0.00% | 21.39% |
| Communication Services | 0.00% | 0.00% | 3.21% | 24.28% |
| Consumer Defense | 0.00% | 0.00% | 34.31% | 27.17% |
| Consumer Cyclical | 0.00% | 0.00% | 1.21% | 30.06% |
| Basic Materials | 0.00% | 0.00% | 2.61% | 43.93% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | FPHAX % Rank | |
|---|---|---|---|---|
| US | 55.98% | 47.91% | 100.00% | 98.27% |
| Non US | 43.23% | 0.00% | 43.87% | 1.16% |
FPHAX - Expenses
Operational Fees
| FPHAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.78% | 0.08% | 25.14% | 68.07% |
| Management Fee | 0.54% | 0.00% | 1.25% | 30.64% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.40% | N/A |
Sales Fees
| FPHAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| FPHAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | 70.73% |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| FPHAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 52.00% | 0.70% | 252.00% | 70.73% |
FPHAX - Distributions
Dividend Yield Analysis
| FPHAX | Category Low | Category High | FPHAX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 3.15% | 36.99% |
Dividend Distribution Analysis
| FPHAX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Semi-Annually | Annually | Quarterly | Annually |
Net Income Ratio Analysis
| FPHAX | Category Low | Category High | FPHAX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 1.36% | -2.53% | 2.53% | 5.99% |
Capital Gain Distribution Analysis
| FPHAX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Semi-Annually | Annually | Annually | Annually |
Dividend Payout History
| Date | Amount |
|---|---|
| Apr 10, 2017 | $0.023 |
| Dec 19, 2016 | $0.183 |
| Apr 16, 2012 | $0.045 |
| Dec 12, 2011 | $0.077 |
| Apr 07, 2011 | $0.035 |
| Dec 13, 2010 | $0.110 |
| Apr 12, 2010 | $0.020 |
| Dec 14, 2009 | $0.115 |
| Apr 20, 2009 | $0.040 |
| Dec 15, 2008 | $0.110 |
| Apr 14, 2008 | $0.020 |
| Dec 17, 2007 | $0.070 |
| Apr 16, 2007 | $0.040 |
| Dec 18, 2006 | $0.030 |
| Apr 10, 2006 | $0.010 |
| Dec 19, 2005 | $0.010 |
| Apr 11, 2005 | $0.005 |
FPHAX - Fund Manager Analysis
Managers
Karim Suwwan de Felipe
Start Date
Tenure
Tenure Rank
Jul 01, 2017
3.25
3.3%
Karim Suwwan de Felipe is portfolio manager of Pharmaceuticals Portfolio, which he has managed since July 2017. Since joining Fidelity Investments in 2010, Mr. Suwwan de Felipe has worked as a research analyst and portfolio manager
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.08 | 23.06 | 7.22 | 20.43 |
